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Abstract
Background: Effective surveillance for infectious diseases is an essential component of public health. There are few studies
estimating the cost-effectiveness of starting or improving disease surveillance. We present a cost-effectiveness analysis the
Integrated Disease Surveillance and Response (IDSR) strategy in Africa.
Methodology/Principal Findings: To assess the impact of the IDSR in Africa, we used pre- and post- IDSR meningococcal
meningitis surveillance data from Burkina Faso (1996–2002 and 2003–2007). IDSR implementation was correlated with a
median reduction of 2 weeks to peak of outbreaks (25
th percentile 1 week; 75
th percentile 4 weeks). IDSR was also correlated
with a reduction of 43 meningitis cases per 100,000 (25
th–40: 75
th-129). Assuming the correlations between reductions in
time to peak of outbreaks and cases are related, the cost-effectiveness of IDSR was $23 per case averted (25
th-$30; 75
th - cost
saving), and $98 per meningitis-related death averted (25
th-$140: 75
th – cost saving).
Conclusions/Significance: We cannot absolutely claim that the measured differences were due to IDSR. We believe,
however, that it is reasonable to claim that IDSR can improve the cost-effectiveness of public health surveillance.
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Introduction
More than 1.5 million children die each year in sub-Saharan
Africa, from diarrhea, malaria, measles, meningitis, respiratory
infections, yellow fever, and HIV/AIDS [1–6]. Well known and
effective interventions are available for controlling and preventing
the diseases that cause these deaths but they are often not applied to
their maximum potential [7–10]. The resulting deaths and the
associated economic costs to society could be reduced if timely
detection and control measures are implemented [11–13]. In
response to this problem, in 1998, countries in the World Health
Organization (WHO) African region adopted a regional strategy
named Integrated Disease Surveillance and Response (IDSR) [14–
16, Table S1]. IDSR is a strategy that seeks to strengthen the ability
of national and regional public health surveillance programs. The
goal of IDSR is to integrate a number of surveillance systems, both
existing and newly formed. This integration should encompass all
levels of public health (from the basic district-level through to the
national level), and should achieve efficiencies by avoiding
duplication of efforts. Areas of activity that IDSR focuses on to
improve efficiency include detection and identification of public
health problems, increased speed of reporting and notification
(especially for immediately notifiable diseases), analysis of data and
interpretation of trends, laboratory confirmation when required,
decision-making about responses, monitoring of progress and
regular evaluation of the surveillance system’s quality (14–16).
The net results of IDSR-implemented reforms in surveillance
systems should be that outbreaks are detected earlier, allowing
quicker public health response (e.g., vaccination campaigns).
Although considerable progress had been achieved with
implementation of the IDSR strategy (see http://www.cdc.gov/
idsr/implementation.htm#progress), the associated economic
benefits (e.g., cases and death prevented, costs of medical
treatments saved by the society, and the value of avoided year of
life lost) are poorly documented. Most studies on economic
evaluation of public health intervention programs in sub-Saharan
Africa have focused on individual disease-specific intervention
activities [17–23]. Relatively few studies have looked at the
economic benefits of surveillance and response activities [24,25].
In a previous study, we analyzed the costs of establishing and
subsequently operating activities for detection and response to the
priority diseases under the IDSR strategy [26]. We add to the
literature by presenting a cost effectiveness analysis of IDSR, in
which we will assume that any average reductions in health
outcomes (e.g., incidence of cases and deaths, outbreak duration)
were due to implementation of IDSR.
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To model the cost-effectiveness of IDSR, we used data from
Burkina Faso because that country had fully established IDSR
leadership and structures at the national level by 2002, with
implementation at regional and district levels in 2003. Burkina
Faso had data, collected using the IDSR-supported surveillance
systems, on several meningitis outbreaks.
The nature of disease surveillance systems makes it impossible to
have a randomly controlled experiment to measure the impact of
IDSR on public health outcomes. We were unable to readily
collect comparable data from another country (e.g., one without
IDSR systems, or one that implemented IDSR systems after
Burkina Faso), and thus we were unable to conduct a comparison
between countries. We therefore relied on observational (before-
and-after) data from outbreaks of meningococcal meningitis to
assess the possible impact of IDSR-related activities in Burkina
Faso. We assumed that any correlations between the start of IDSR
activities, which includes both surveillance and response to disease
activity detected, and changes in the epidemiology of meningitis
outbreaks were due primarily to IDSR. With this assumption, we
calculated, on an outbreak basis, costs per case, per death and per
sequelae prevented. There could be other reasons for any
correlations that we measured (see discussion section).
As most health care and IDSR activities in Burkina Faso are
funded by the government, we took the perspective of the
government-funded public health care system (i.e., we only
recorded costs and savings incurred by the national government);
costs incurred by households were not included. All cost data were
recorded in local currency values and then converted into US
dollar values using the mean annual exchange rate. We used the
general consumer price index from Burkina Faso [27] and a
discount rate of 3% to adjust all costs into 2002 US dollars
equivalent.
Epidemiological data
We obtained from the WHO Multi-Diseases Surveillance
Center inOuagadougou annualpopulationdataand districtlevel
reports of weekly meningitis cases and deaths from Burkina Faso
for the years 1996–2007 (see Table S2). We then calculated the
weekly incidence and mortality, expressed as cases and deaths
per 100,000 inhabitants, by dividing the number of new cases
and deaths occurring per week by the mean annual population of
each reporting district. A 1988 study in The Gambia found that
27 out of 154 (17.5%) survivors of bacterial meningitis had
generalized neurolog i c a ls e q u e l a e[ 2 8 ]W et h e r e f o r ea s s u m e d
20% of meningitis survivors would have neurological defects
(sequelae).
We sorted the data into two groups: before (1996–2002) and
after (2003–2007) IDSR implementation at district level. During
this study period, all meningitis outbreaks in Burkina Faso only
occurred between January and June (23-week period). For each
group, we examined the weekly incidence rates in relation to the
WHO recommended alert threshold (5 cases per 100,000) and
epidemic threshold (10 cases per 100,000) [29]. We defined the
start (end)of an outbreak when cases in a district exceeded
(returned below) the epidemic threshold. For each outbreak, we
calculated the time-to-peak of the outbreak as the number of weeks
elapsed from the first alert threshold to the week with the
maximum weekly incidence (i.e., the peak of the outbreak). We
also calculated the time to reach the median, 25
th and 75
th
percentiles of cumulative total incidence and mortality.
For each group of outbreaks before and after IDSR implemen-
tation (start 2003), we calculated the median, 25
th and 75
th
percentile for each of the following health outcomes: weekly and
cumulative total incidence, mortality and sequelae.
Data analysis
We first plotted the average weekly incidence rates over the time
period studied and the median weekly incidence and mortality
before and after IDSR implementation over the 23-week period of
meningitis outbreaks. We then compared the health outcomes (i.e.,
incidence, mortality, time to peak and time to reach a set
percentile of total cases per outbreak) using the Mann-Whitney test
using SAS statistical software version 9.1 (SAS Institute Inc., Cary,
NC, USA). In 1996 there was an ‘‘unusually’’ large epidemic of
meningitis in Burkina Faso. We therefore examined the influence
of 1996 data on the IDSR effectiveness measures by re-running
the analyses excluding 1996 data.
Response to outbreaks: Vaccine importation
As IDSR encompasses a deliberate response factor, it is
plausible that vaccine imports may increase post-IDSR imple-
mentation. In order to assess potential correlation between IDSR
implementation and meningococcal vaccine importation, we
obtained estimates of the doses of vaccine imported by the
Burkina Faso government from the WHO International Consul-
tative Group, UNICEF, and GlaxoSmithKline Biologicals.
Vaccine data were also collected from the WHO disease outbreak
website (http://www.who.int/csr/don/en/index.html) (Tables S3
and S4). We statistically tested if annual importation of doses was
impacted by IDSR implementation using the following general
linear regression:
Doses imported per year~
InterceptzYearzIDSR Implementation Perioddummyz error term
Where IDSR implementation period was recorded as a dummy
variable (Pre-IDSR =0; Post-IDSR=1). We ran six models, each
time varying the dependent variable (doses imported) as follows:
Total annual doses imported (including 1996 data); Total annual
doses imported (excluding 1996 data); Doses per 100,000
population in whole country (including 1996 data);
Doses per 100,000 population in whole country (excluding 1996
data); Doses per 100,000 population in districts where outbreaks
occurred (including 1996 data); and, doses per 100,000 population
in districts where outbreaks occurred (excluding 1996 data). To
check for autocorrelation, we calculated the Durbin-Watson
statistic for each regression.
Costs
We used the costs of IDSR-related activities reported in our
previous study [26; see also Table S5]. The costs include those due
to surveillance and response. In the case of meningitis, response is
mostly treatment of those ill and vaccination of populations near a
victim (e.g., those in the same village). The cost data for each
activity included personnel, transportation items, office consum-
able goods, public awareness campaigns, laboratory and response
materials and supplies, and capital items [26].
We also obtained direct medical care costs incurred by the
government to treat a patient with meningitis related-illness at
district health facility ($53) and regional hospital ($71) during the
2002 epidemic situation (unpublished data, Ministry of Health,
Burkina Faso; see Table S6)). These estimates include only the
immediate costs of meningitis case management (e.g., consultation
and hospitalization fees, drugs and other essential consumables,
and laboratory specimen testing). As the study perspective is the
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the costs for transportation to the health facility, provision of long-
term care for patients with severe sequelae and loss of productivity
due to morbidity and premature death.
Cost-effectiveness analysis
Assuming that any measured differences between health
outcomes (i.e., after IDSR minus before IDSR) are due to IDSR,
we calculated the cost-effectiveness in net cost (in dollars) per
outcome averted using the following general formula:
Net Cost per outcome averted~Annual Cost of IDSR minus
Cost per case multiplied by ½ number of cases averted 
divided by number of outcomes averted
where outcomes averted were cases, deaths or sequelae.
We used the above formula to calculate the cost-effectiveness
ratios for the median, 25
th,a n d7 5
th percentiles differences in
cases, deaths or sequelae averted before and after IDSR. The
median (25
th,7 5
th) cost effectiveness ratio was calculated using
the median (25
th,7 5
th) annual cost of IDSR activities In this
equation, a negative result indicates net cost savings, when the
cost savings of IDSR (i.e., cost of treatments avoided due to cases
averted) outweigh the costs of IDSR activities (surveillance and
response).
We also determined the net cost per capita of IDSR as follow:
Net cost per capita ~
Tatal cost of IDSR per 100,000 persons minus Treatment cost ð
averted per 100,000 personsÞ divided by 100,000 population:
In this equation, the per capita IDSR costs were calculated
using data from the whole country [26] while the costs of
treatment averted come from districts that reported outbreaks.
Sensitivity analysis
Regardless of IDSR activities, any measured alteration in the
epidemiology of meningitis, including any reduction in cases,
could have been due to naturally occurring disease cycles. To
remove any unknown effect of disease cycles or specific years, we
individually compared health outcomes (incidence of cases,
mortality, sequelae, and time-to-peak of outbreak) between each
outbreak before IDSR and each outbreak that occurred after
IDSR implementation. This analysis removes the element of time
sequence, and we only compare outcomes before-versus-after the
start of IDSR. Specifically, we used the following general
formula:
Outcomeoutbreak X afterIDSR ðÞ {Outcomeoutbreak Y beforeIDSR ðÞ
Figure 1. Weekly number of meningococcal meningitis cases (all serotypes) reported during the meningitis season (week 1 to 23)
and number of doses of meningococcal vaccine imported from 1996 to 2007 in Burkina Faso. Note: District level weekly new meningitis
cases from Burkina Faso for the years 1996–2007 were obtained from the WHO Multi-Diseases Surveillance Center in Ouagadougou, Burkina Faso.
Incidence recorded in a particular district experiencing a meningitis outbreak - the incidence data do not apply to the entire country. For list of
districts reporting outbreaks recorded in this Figure, see Table S2. Doses of vaccine include all bivalent (AC), trivalent (ACW), and tetravalent (ACWY)
polysaccharides imported by the government of Burkina Faso through different organizations (WHO-ICG, UNICEF, MSF, and GlaxoSmithKline
Biologicals). Dates of vaccine shipment are representation for purpose of graphing (see also Tables S3 and S4).
doi:10.1371/journal.pone.0013044.g001
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th and 75
th percentiles)
of number of meningitis deaths per outbreak. Data source: WHO Multi-Diseases Surveillance Center, Ouagadougou, Burkina Faso. For each
weekly mortality rate, we calculated the median, 25
th and 75
th percentile of the 105 and 82 outbreaks before IDSR and 86 outbreaks after IDSR. Before
IDSR, the median (25
th and 75
th percentile) cumulative number of deaths per outbreak was 23.8 (17.9 and 35.9) per 100,000 inhabitants when 1996
data were included and was 20.5 (16.1 and 30.3) per 100,000 inhabitants when 1996 data were excluded. After IDSR, the median (25
th and 75
th
percentile) cumulative number of deaths per outbreak was 12.6 (8.8 and 21.3) per 100,000 inhabitants.
doi:10.1371/journal.pone.0013044.g003
Figure 2. Comparison before (1996–2002) and after (2003–2007) IDSR implementation: weekly median (25
th and 75
th percentiles)
of new cases of meningitis per outbreak. Note: Data source: WHO Multi-Diseases Surveillance Center, Ouagadougou, Burkina Faso. For each
weekly incidence rate, we calculated the median, 25
th and 75
th percentile of the 105 and 82 outbreaks before IDSR and 86 outbreaks after IDSR.
Before IDSR, the median (25
th and 75
th percentile) cumulative number of meningitis cases per outbreak was 185.0 (139.5 and 377.0) per 100,000
inhabitants when 1996 data were included and was 167.9 (135.3 and 281.0) per 100,000 inhabitants when 1996 data were excluded. After IDSR, the
median (25
th and 75
th percentile) cumulative number of deaths per outbreak was 142.0 (100.3 and 248.2) per 100,000 inhabitants.
doi:10.1371/journal.pone.0013044.g002
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2003, and Y is a particular outbreak before IDSR started.
Using this formula, we generated 9,030 paired comparisons
(105 outbreaks before IDSR x 86 outbreaks after IDSR) in
outcomes for each of the following variables: incidence of cases,
mortality, sequelae, and time-to-peak of outbreak. We also
examined the influence of 1996 data on these comparisons by
re-running the simulation excluding all outbreaks that occurred in
1996 (giving 7,052 paired comparisons).
We then plotted the distribution of the differences between the
paired comparisons (with and without the 1996 data) for the time
to peak, and incidence of cases and mortality. We also calculated
the median, 25
th and 75
th percentiles for the cases, deaths and
sequelae averted (with and without the 1996 data). Similarly, we
calculated the simple average, minimum and maximum of the
differences in these health outcomes. Finally, we used the data
from the paired comparisons to calculate cost-effectiveness ratios
as described earlier.
Results
Health outcomes and effectiveness measures
Based on our definition of outbreaks (10 per 100,000 – see
earlier), we identified 105 outbreaks before adoption of IDSR and
86 after adoption of IDSR (Table S2). The mean weekly
meningitis cases per outbreak recorded from 1996 to 2007 at
Table 1. Comparison before (1996–2002) and after (2003–2007) IDSR implementation: Total number of meningitis cases and
deaths, time to peak of outbreak, and time to reach total cases and deaths.
Including 1996 data Excluding 1996 data
Outcome measures Before After Difference p-value* Before After Difference p-value*
(n=105) (n=86) (n=82) (n=86)
Total cumulative cases
(per 100,000)
Mean 346 211 2135 0.0267 228 211 217 0.034
25th percentile
{ 140 100 240 135 100 235
50th percentile
{ 185 142 243 168 142 226
75th percentile
{ 377 248 2129 281 248 233
Total cumulative deaths
(per 100,000)
Mean 35 16 219 ,0.0001 26 16 210 ,0.0001
25th percentile
{ 18 9 291 6 9 27
50th percentile
{ 23 13 210 21 13 28
75th percentile
{ 36 21 215 30 21 29
Time-to-peak of
outbreak
1 (weeks)
Mean 6 4 22 ,0.0001 6 4 22 ,0.0001
25th percentile
{ 43 213 3 0
50th percentile
{ 64 226 4 22
75th percentile
{ 95 248 5 23
Time to reach % total
cases
# (weeks)
25% of cases
" 10.5 10.2 20.3 0.1578 10.4 10.2 20.2 0.2954
50% of cases
" 12.6 12 20.7 0.0123 12.5 12 20.5 0.1081
75% of cases
" 14.4 13.6 20.7 0.015 14.1 13.6 20.5 0.0404
Time to reach % total
deaths
# (weeks)
25% of deaths
" 9.9 9 20.9 0.0052 9.6 9 20.6 0.0361
50% of deaths
" 12.2 11.6 20.6 0.0193 11.9 11.6 20.3 0.1313
75% of deaths
" 14 13.6 20.4 0.0609 13.7 13.6 20.1 0.4307
*p-value of Mann-Whitney score test for two-sample groups. We compared health outcomes for each of the 105 outbreaks before IDSR with each of the 86 outbreaks
after IDSR implementation. We then re-ran these paired comparisons excluding the 1996, before IDSR data. Negative figure indicates lower number per outbreak after
IDSR than before IDSR implementation.
{These represented the 25
th percentile, 50
th percentile, and 75
th percentile of the total number of cases and deaths and the time to peak before and after IDSR.
1Time to peak of outbreak represented the time elapsed from reaching the alert threshold of a weekly incidence of 5 cases per 100,000 inhabitants to the week with the
maximum weekly incidence.
#Time to reach total cases and deaths represented the time interval between the first week of each calendar year and the week during the outbreak period when the
total cases and deaths were reached.
"These are the average time for outbreaks to reach the 25th, 50th, and 75
th percent of total cases and deaths. For example, before IDSR it took 10.5 weeks during an
outbreak to reach 25% of all cases attributed to that outbreak.
Data source: WHO Multi-Disease Surveillance Center, Ouagadougou, Burkina Faso (see Table S2).
doi:10.1371/journal.pone.0013044.t001
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total incidence and mortality, time-to-peak of outbreak, and time
to reach a fixed percentage of total incidence and mortality rates
per outbreak are showed in Table S2. The size of these outbreaks
was variable and 1996 was the largest epidemic year recorded
(Figure 1). We observed from Figure 1 some evidence that, after
IDSR implementation in 2003, there were lower peaks-of-
incidence and possibly lower cumulative total incidence-per-
outbreak. However, lower peak incidence after IDSR is not
uniform, as we note that the peak incidence in 2007 is greater than
the peaks in all but two years (1996 and 1997) before IDSR
implementation.
The median and the 25
th and 75
th percentiles of the weekly
number of meningitis cases and deaths before and after IDSR
implementation are presented in Figures 2 and 3, respectively. The
peak of the median value of the number of meningitis cases and
deaths after IDSR implementation is lower than the peaks of the
before IDSR median values (with and without 1996 data).
However, the 75
th percentile after IDSR implementation is
greater than some of the median values before IDSR, indicating
that IDSR implementation does not always equate with lower
number of cases (Figures 2 and 3).
The pattern of differences in peaks is also seen when comparing
cumulative cases. After IDSR implementation, the average and
median (50
th percentile) incidences per outbreak dropped by 135
per 100,000 and 40 per 100,000 (p-value 0.0001, Table 1),
respectively. Time-to-peak, time to reach a set percentage of total
cases, and time to reach a set percentage of total deaths were all
reduced after IDSR; however, some p-values of the difference
were greater than 0.05 (Table 1). The removal of 1996 data did
reduce the size of the differences, but differences did remain,
showing that IDSR implementation was correlated with reduction
in incidence of cases and mortality, and time-to-peak (Table 1).
Vaccine imports
We did not find any evidence of a statistically significant
correlation associated between doses of vaccine imported and
outbreaks (Figure 1, Table S7). There were some obvious increases
in recorded importation of vaccine in some of the years that had
‘‘large’’ outbreaks (e.g., 1996, 2001, and 2007). On the other hand,
in some years there were little or no recorded imports, regardless of
peak incidence (e.g., 1999, 2000, and 2005). We note that we had
difficulty in obtaining some of the vaccine import data, particularly
for the earlier years examined. We conclude that IDSR has not had
anappreciableimpact ondosesofvaccineimported.Thus,whenwe
considered costs associated with IDSR we did not include any costs
associated with increased doses of vaccine used.
Cost-effectiveness analysis
The median net cost of averting a case of meningitis was $23 per
meningitis case averted (25
th percentile: $30; 75
th percentile: cost
savings), and the median cost per death and sequelae averted were
$98 and $126, respectively (Table 2). The median cost of operating
IDSR was $0.01 per capita (25
th: $0.01; 75
th: cost saving) (Table 2).
Excluding the 1996 data notably impacted most estimated cost-
effectiveness ratios. For example, excluding 1996 data caused the
Table 2. Cost-effectiveness (2002 US $) correlated with IDSR impact on meningitis cases and deaths averted per outbreak in
Burkina Faso.
Including 1996 data
Median
*
Excluding 1996 data
Median
*
(25th 75th percentiles)( 25
th 75th percentiles)
Total cost of IDSR
1 3,684 3,684
Activities (per 100,000)
Treatment costs
# 2,675 1,609
Avoided (per 100,000) (2,473 8,018)( 2,175 2,037)
Net IDSR costs 1,009 2,075
(per 100,000) (1,211 savings)( 1,509 1,647)
Cost per case 23 80
Averted (30 savings)( 43 25)
Cost per death 98 263
Averted (140 savings)( 207 182)
Cost per sequelae
" 126 669
Averted (212 savings)( 296 358)
Cost per capita 0.01 0.02
(0.01 savings)( 0.02 0.02)
Note: We took the perspective of the government-funded public health care system. We compared health outcomes for each of the 105 outbreaks before IDSR with
each of the 86 outbreaks after IDSR implementation. We then re-ran these paired comparisons excluding the 1996, before IDSR data.
*The median cost-effectiveness was calculated using the median cost of IDSR activities and the difference in the number of outcomes of the median (25
th percentile –
75
th percentile) outbreak before and the median (25
th percentile –75
th percentile) after IDSR implementation, respectively.
1See reference 26. No vaccine cost included because no evidence found of incremental importation of vaccine doses correlated with implementation of IDSR (see
Figure 1 and also Table S7).
#We estimated the treatment cost-saving by multiplying the mean medical cost ($62.25) per meningitis patient by the difference in the number of cases per outbreak
that occurred before IDSR versus after IDSR.
"We calculated the number of sequelae by assuming 20% of all meningitis illness-related survivors have neurological defects.
Data Source: IDSR cost data (see reference 26). We obtained annual population data and district level weekly meningitis cases and deaths from the WhO-MDSC in
Ouagadougou, Burkina Faso.
doi:10.1371/journal.pone.0013044.t002
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per case averted (Table 2). We also found that removing the 1996
data increased the median cost per capita to $0.02 (Table 2).
Sensitivity analysis
In more than 50% of the pairings in the paired outbreak
analysis, which removes the influence of time and disease cycles,
the outbreaks after IDSR implementation had lower incidence of
cases and mortality, as well as shorter time-to-peak (Figure 4). The
median, mean, maximum, and 75
th percentiles of all the paired
outbreaks all showed a reduction in incidence of cases, deaths and
sequelae associated with outbreaks occurring after IDSR imple-
mentation (Table 3). However, the data from paired-outbreak
comparisons resulted in some lower (i.e., cheaper) median cost-
effectiveness estimates (Table 4).
Discussion
The IDSR strategy is focused on improving the collection and
analysis of infectious disease surveillance data to more rapidly and
accurately detect, and respond to, disease outbreaks. This should
hopefully reduce the overall burden of disease [14–16]. Our results
show that, in Burkina Faso, IDSR implementation at a district
level was correlated with statistically significant reductions in time-
to-peak of outbreak and reductions in total cumulative incidence
of cases and mortality. Assuming that such correlations are
indicative of causation, our analysis determined that the cost-
effectiveness of IDSR ranged from cost savings to cost of $80 per
case averted, and from cost savings to $263 per death averted. Our
cost-effectiveness estimates were lower (i.e., cheaper), but not
dissimilar, than earlier estimates for a meningococcal meningitis
mass vaccination campaign in Burkina Faso [21,30]. These earlier
studies estimated US $133 per case and US $2,397 per death
averted, uncorrected for inflation [21,30]. Immunization cam-
paigns in the region for yellow fever, neonatal tetanus, poliomy-
elitis, and diphtheria reported cost effectiveness ratios of US $281
to $20,591 per death averted [31,32].
We could not find any statistically significant evidence of an
increase in vaccine imports. We can only speculate that the
reduced incidence of cases and deaths are due to IDSR allowing
public health officials to better target existing resources to
outbreaks. That is, the IDSR system enables public health officials
to identify and get to an outbreak sooner, and be more certain
which villages and areas need interventions.
The study’s main limitation is the uncertainty in assuming that
the reductions in cases were due to IDSR. We do not have enough
evidence to claim the degree that the differences that we measured
were due to IDSR. As mentioned earlier, the nature of a public
health system such as IDSR prevents us from designing and
conducting a controlled scientific experiment. It is possible that the
changes in epidemiology that we recorded were due to changes in
other factors, such as a change in the circulating serogroups and
strains of Neisseria meningitidis. For the time period studied, an
examination of the WHO data shows that the main circulating
strain was serogroup A, although serogroup W135 co-circulated
[33, Table S8]. Two studies, which analyzed in greater detail the
specimens and data, found that there were some differences in
strains (sequence types) of circulating serogroup A over time, with
serogroup 7 recorded more frequently after 1995 – though both
strains were from the same clonal group [34, 35, Table S8].
Figure 4. Sensitivity analysis: Distribution of paired compari-
son of outbreaks before and after IDSR: Difference in time-to-
peak, incidence rate, and mortality rate. Note: Comparison of data
of each of the 105 outbreaks before IDSR with each of the 86 outbreaks
after IDSR. Removing 1996 data reduces total outbreaks before IDSR to
82. Effects on outcomes correlated with IDSR are represented on the
horizontal axes: negative numbers indicated reducing effects and
positive numbers indicated increasing effects on time-to-peak of
outbreak (Panel A), number of cases per outbreak (Panel B), and
number of deaths per outbreak (Panel C).
doi:10.1371/journal.pone.0013044.g004
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(typically less than 20 isolates per year) and are collected in a non-
random fashion (i.e., convenience samples).
Other limitations include the fact that our retrospective survey
may not have fully captured all data. This would be due to the
limitations of public data records (e.g., no vaccine distribution and
use records at country level) or ‘‘readily’’ accessible program
records of specific public health projects (such as meningitis
specific vaccine program) that run parallel to the national public
health system. Further, we assumed that the accuracy of recording
cases and deaths due to meningitis remained unchanged during
the period studied. The implementation of IDSR could have
Table 3. Sensitivity analysis of number of meningitis cases, deaths and sequelae averted correlated with introduction of IDSR:
Paired-comparison of outbreaks before (1996–2002) and after (2003–2007) IDSR implementation:
Outcomes measures# Including 1996 data
{ Excluding 1996 data
{
Median
" Average
"* Median
" Average
"*
(25th percentile 75th
percentile) (minimum maximum)
(25th percentile 75th
percentile) (minimum maximum)
Total cumulative cases
averted (per 100,000)
248
(58 2201)
2134
(666 24,769)
227
(80 2115)
217
(666 2877)
Total cumulative deaths
averted (per 100,000)
210
(21 225)
219
(61 2250)
28
(1 217)
210
(61 2102)
Total cumulative sequelae
averted (per 100,000)
215
(18 265)
244
(267 22,092)
28
(25 238)
26
(267 2375)
{We compared health outcomes for each of the 105 outbreaks before IDSR with each of the 86 outbreaks after IDSR implementation. We then re-ran these paired
comparisons excluding the 1996, before IDSR data.
#Number of health outcomes averted was calculated using the following equation: Outcome outbreak X after IDSR – Outcome outbreak Y before IDSR, where X for outbreak after
IDSR and Y for outbreak before IDSR.
We calculated the number of sequelae by assuming 20% of all meningitis illness-related survivors have neurological defects (see main text).
"Negative figure indicates reduction in cases, deaths, and sequelae per outbreak after IDSR implementation.
*These columns present the simple average, minimum and maximum of the differences in health outcomes between paired outbreaks.
Data Source: WHO Multi-Diseases Surveillance Center, Ouagadougou, Burkina Faso.
doi:10.1371/journal.pone.0013044.t003
Table 4. Sensitivity analysis of total cost of IDSR, treatment cost of meningitis cases avoided, and cost-effectiveness
*: Paired
comparison of outbreaks before (1996–2002) and after (2003–2007) IDSR implementation.
Including 1996 data Excluding 1996 data
Median
{ Median
{
(25th percentile 75th percentile) (25th percentile 75th percentile)
Total cost of IDSR 3,684 3,684
Activities (per 100,000)
Treatment costs
# 2,982 1,662
Avoided (per 100,000) (23,592 12,503) (24,999 7,159)
Net IDSR costs 568 2,022
(per 100,000) (7,276 savings) (8,683 savings)
Cost per case 15 76
Averted (126 savings) (108 savings)
Cost per death 68 270
Averted (7,276 savings) (6,679 savings)
Cost per sequelae 46 239
Averted (408 savings) (346 savings)
Cost per capita 0.01 0.02
(0.07 savings) (0.09 savings)
*We took the perspective of the government-funded public health care system. We measured the effectiveness by subtracting the number of cases, deaths, and
sequelae of each of the 86 outbreaks after IDSR from each of the 105 outbreaks before IDSR. We then re-ran the analysis excluding the 1996, before IDSR data.
{We calculated the median, 25
th and 75
th percentile cost-effectiveness based on the difference of the generated health outcomes (after IDSR versus before IDSR)
distribution.
#We estimated the treatment costs avoided by multiplying the mean medical cost ($62.25) per meningitis patient by the number of cases averted.
Data Source: WHO Multi-Diseases Surveillance Center, Ouagadougou, Burkina Faso. We calculated the number of sequelae by assuming 20% of all meningitis illness-
related survivors have neurological defects.
doi:10.1371/journal.pone.0013044.t004
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IDSR. However, it is impossible to assess the degree, and therefore
impact, of any changes in accuracy over time.
We believe, even with the study limitations, that these results
indicate that IDSR is likely to be a cost-effective public health
system. A completely accurate accounting of its benefits to society,
such as money and lives saved has yet to be documented. It is also
clear, however, that IDSR is not a complete solution to eliminating
the burden of meningococcal meningitis. Given the difficulty of
measuring the impact of surveillance and response systems, it may
well be that policy-makers will have to make assessments of the
value of IDSR and similar systems using the type of data we
presented here.
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